Cypress, California, United States
NCT Number: NCT02133339
Single Ascending Dose Study of TRN-157 in Healthy Subjects
This single ascending dose study is to determine and evaluate the safety and tolerability of TRN-157 in approximately 40 healthy subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subject has provided written informed consent
- The subject is male or female 18 to 65 years of age
- If the subject or subject's partner is of childbearing potential, a medically acceptable form of contraception will be
- Non-smoker
- Good general health
- Willing to abstain from alcohol, caffeine, and xanthine-containing beverages
- The subject is compliant and available throughout the entire study period
Exclusion criteria
- Current diagnosis, as per subject or investigator or screening assessment, of:
- unstable or uncontrolled disease in any organ system (including cardiovascular) on present therapy
- history of narrow angle glaucoma
- history of alcohol abuse within the past 5 years
- history of smoking within the past 6 months
- positive result for the alcohol and/or drugs of abuse
- weight > 100 kg or < 50 kg
- clinically significant abnormal ECG
- history of clinically significant (per the Investigator) disease or disorder
- any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results
- Abnormal vital signs defined as any of the following:
- Systolic blood pressure ≥ 140 mmHg
- Diastolic blood pressure ≥ 90mmHg
- Heart rate < 40 or > 85 beats per minute
- Fever or other clinically significant physical exam findings
- Current or history of clinically significant respiratory disease, including asthma, emphysema, chronic bronchitis, or cystic fibrosis
- History or current symptom(s) of respiratory tract inflammation
- Inability to perform reproducible spirometry in accordance with American Thoracic Society (ATS) guidelines
- Abnormal FEV1, FVC, or FEV1/FVC (FEV1 or FVC < 80% of predicted or FEV1/FVC ratio < 0.7)
- FEV1 variability > 10% between study visits
- Female of childbearing potential with a positive serum pregnancy test or currently breastfeeding
- Currently being treated for hypertension or taking any other medications that affect blood pressure significantly
- Inability to perform acceptable, quality serial spirometry or any other study procedures
- Positive screen for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or HIV antibody
Treatment and study plan
TRN-157
DrugPlacebo
DrugPrimary outcomes
-
Safety and tolerability as determined by number of subjects with adverse events
Time frame: 1 week
Secondary outcomes
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Area Under the Plasma Concentration-Time Curve from Zero to the Time of the Last Measurable Concentration (AUC0-t)
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Area Under the Plasma Concentration-Time Curve from Zero to Infinity (AUC0-inf)
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Peak Plasma Concentration (Cmax)
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Time to Peak Plasma Concentration (tmax)
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Half-Life (t½)
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Elimination Rate Constant (kel)
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Volume of Distribution at Steady State after Non-IV Administration (Vss/F)
-
Determination of pharmacokinetic parameters
Time frame: 1 week
Total Plasma Clearance after Non-IV Administration (CL/F)
Sponsors and collaborators
Lead sponsor
Theron Pharmaceuticals, Inc.
Industry
Registry information
Official study title
A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects
Important dates
- Study start
- 2014
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- May 8, 2014
- Registry last updated
- Oct 31, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Home-based Body Weight Exercise With Blood Flow Restriction (BFR): Feasibility of a Novel Rehabilitation Intervention in COPD Patients (HomeBFR-COPD)
NCT05984823
Chronic Disease, Chronic Obstructive Pulmonary Disease
Leicester, Leicestershire, United Kingdom
View Trial DetailsClinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD
NCT05572333
COPD, Chronic Disease
Frankfurt, Germany
View Trial DetailsAnalysis of the Dynamics of the Lung Microbiota During Acute Exacerbation of COPD Requiring Admission to Intensive Care Unit
NCT03641235
Chronic Disease, Chronic Obstructive Pulmonary Disease
Bordeaux, France
View Trial DetailsCOPD Care Pathway Among Patients With Cancer
NCT05984680
Chronic Disease, Chronic Obstructive Pulmonary Disease
Winston-Salem, North Carolina, United States
View Trial Details